Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-wg55d Total loading time: 0 Render date: 2024-05-15T08:34:10.079Z Has data issue: false hasContentIssue false

Chapter 9 - Treatment of Blepharospasm

Published online by Cambridge University Press:  02 November 2023

Daniel Truong
Affiliation:
University of California, Riverside
Dirk Dressler
Affiliation:
Hannover Medical School
Mark Hallett
Affiliation:
National Institutes of Health (NIH)
Christopher Zachary
Affiliation:
University of California, Irvine
Mayank Pathak
Affiliation:
Truong Neuroscience Institute
Get access

Summary

Blepharospasm is the most frequent cranial dystonia and consists of involuntary, symmetric, tonic or clonic bilateral contractions of the orbicularis oculi muscle, resulting in partial or complete eye closure. Blepharospasm can be primary (idiopathic), secondary or psychogenic. Primary blepharospasm is an adult-onset focal dystonia, manifesting with forceful eyelid closures. Rarely, blepharospasm is secondary to structural brain lesions, drug-induced or other neurodegenerative conditions like atypical parkinsonism. Blepharospasm’s severity may range from increased blinking frequency (only causing minor discomfort) to a persistent and forceful eyelid closure, leading to functional blindness

The orbicularis oculi muscle is the most frequently involved muscle; other involved muscles may include the corrugator supercilii, the procerus and the frontalis. Botulinum neurotoxin (BoNT) is considered the first-line treatment for blepharospasm. Typically, four injections are administered in the orbital or preseptal portion of the orbicularis oculi muscle, but the number of injections can be increased to include the lateral canthus and the pretarsal component of the orbicularis oculi. This chapter diagrams typical injection sites, tabulates dose ranges for different preparations of neurotoxin and lists frequencies of common adverse events.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Colosimo, C, Bologna, M, Berardelli, A (2015). How do I examine blepharospasm? Mov Disord Clin Pract, 2, 449.CrossRefGoogle ScholarPubMed
Colosimo, C, Tiple, D, Berardelli, A (2012). Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox Res, 22, 265–73.CrossRefGoogle ScholarPubMed
Defazio, G, Hallett, M, Jinnah, HA, Conte, A, Berardelli, A (2017). Blepharospasm 40 years later. Mov Disord, 32, 498509.Google Scholar
Duarte, GS, Rodrigues, FB, Marques, RE et al. (2020). Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev, 11, CD004900.Google ScholarPubMed
Hallett, M (2002). Blepharospasm: recent advances. Neurology, 59, 1306–12.CrossRefGoogle ScholarPubMed
Marsili, L, Bologna, M, Jankovic, J, Colosimo, C (2021). Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal. Expert Opin Drug Saf, 20, 695705.CrossRefGoogle ScholarPubMed
Marur, T, Tuna, Y, Demirci, S (2014). Facial anatomy. Clin Dermatol, 32, 1423.CrossRefGoogle ScholarPubMed
Mascia, MM, Dagostino, S, Defazio, G (2020). Does the network model fits neurophysiological abnormalities in blepharospasm? Neurol Sci, 4, 2067–79.Google Scholar
Owecki, MK, Bogusz, H, Magowska, A (2017). Henri Meige (1866–1940). J Neurol, 264 , 2348–50.CrossRefGoogle ScholarPubMed
Ramirez-Castaneda, J, Jankovic, J (2013). Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins (Basel), 5, 249–66.CrossRefGoogle ScholarPubMed
Simpson, DM, Hallett, M, Ashman, EJ et al. (2016). Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 86, 1818–26.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×